Overview Dividends

(TOI) Oncology Institute - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68236X1000

Oncology Services, Infusion, Dispensary, Clinical Trials

TOI EPS (Earnings per Share)

EPS Growth (3Y CAGR): 58.12%
EPS Trend (3Y Correlation): 75.8%

TOI Revenue

Revenue Growth (3Y CAGR): 24.92%
Revenue Trend (3Y Correlation): 98.3%

Description: TOI Oncology Institute October 28, 2025

The Oncology Institute, Inc. (NASDAQ: TOI) is a U.S.–based provider of comprehensive oncology services, operating through three segments: Dispensary, Patient Services, and Clinical Trials & Other. Its offerings span physician-led care, in-house infusion and dispensary, radiation, outpatient blood-product transfusion, and a suite of patient-support programs such as 24/7 assistance, counseling, and educational seminars.

In addition to direct care, TOI manages and conducts clinical trials for pharmaceutical and medical-device sponsors, and runs specialized programs including palliative care, stem-cell transplantation, and other tertiary-care delivery models targeting adult and senior cancer patients.

Key industry drivers that affect TOI’s outlook include the aging U.S. population (the 65+ cohort is projected to reach 22 % of the total by 2035), rising prevalence of cancer diagnoses, and expanding reimbursement for outpatient infusion and clinical-trial services. Recent quarterly filings (Q2 2024) show TOI’s revenue grew 12 % YoY to $84 million, with a patient-volume increase of 9 % and an operating margin of 8 %, reflecting both higher utilization and improved cost efficiencies.

For a deeper quantitative view of TOI’s valuation metrics, you may find the ValueRay platform useful.

TOI Stock Overview

Market Cap in USD	444m
Sub-Industry	Health Care Equipment
IPO / Inception	2021-11-15

TOI Stock Ratings

Growth Rating	35.6%
Fundamental	38.7%
Dividend Rating	-
Return 12m vs S&P 500	1,128%
Analyst Rating	5.0 of 5

TOI Dividends

Currently no dividends paid

TOI Growth Ratios

Growth Correlation 3m	46.9%
Growth Correlation 12m	94.7%
Growth Correlation 5y	-72.7%
CAGR 5y	9.77%
CAGR/Max DD 3y (Calmar Ratio)	0.10
CAGR/Mean DD 3y (Pain Ratio)	0.17
Sharpe Ratio 12m	0.90
Alpha	993.07
Beta	0.109
Volatility	84.37%
Current Volume	1878.4k
Average Volume 20d	1905.2k
Stop Loss	3.8 (-7.1%)
Signal	-0.56

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-65.9m TTM) > 0 and > 6% of Revenue (6% = 25.5m TTM)

FCFTA -0.08 (>2.0%) and ΔFCFTA 18.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 9.43% (prev 22.46%; Δ -13.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.06 (>3.0%) and CFO -10.2m > Net Income -65.9m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (932.0m) change vs 12m ago 1147 % (target <= -2.0% for YES)

Gross Margin 14.60% (prev 15.33%; Δ -0.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 250.1% (prev 201.0%; Δ 49.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.09 (EBITDA TTM -48.3m / Interest Expense TTM 10.8m) >= 6 (WARN >= 3)

Altman Z'' -7.13

(A) 0.25 = (Total Current Assets 104.8m - Total Current Liabilities 64.8m) / Total Assets 159.8m

(B) -1.55 = Retained Earnings (Balance) -247.4m / Total Assets 159.8m

warn (B) unusual magnitude: -1.55 — check mapping/units

(D) -1.47 = Book Value of Equity -247.4m / Total Liabilities 168.8m

Total Rating: -7.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.74

1. Piotroski 2.50pt = -2.50

2. FCF Yield -2.53% = -1.26

3. FCF Margin -3.08% = -1.16

4. Debt/Equity -11.48 = -2.50

5. Debt/Ebitda -1.51 = -2.50

6. ROIC - WACC (= -68.36)% = -12.50

7. RoE data missing

8. Rev. Trend 98.25% = 7.37

9. EPS Trend 75.75% = 3.79

What is the price of TOI shares?

As of November 06, 2025, the stock is trading at USD 4.09 with a total of 1,878,428 shares traded.
Over the past week, the price has changed by -12.98%, over one month by +7.35%, over three months by +3.28% and over the past year by +1360.71%.

Is Oncology Institute a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Oncology Institute (NASDAQ:TOI) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 38.74 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TOI is around 4.04 USD . This means that TOI is currently overvalued and has a potential downside of -1.22%.

Is TOI a buy, sell or hold?

Oncology Institute has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy TOI.

Strong Buy: 1
Buy: 0
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TOI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7	71.1%
Analysts Target Price	7	71.1%
ValueRay Target Price	4.4	7.3%

TOI Fundamental Data Overview October 27, 2025

Market Cap USD = 444.1m (444.1m USD * 1.0 USD.USD)
P/S = 1.0466
P/B = 0.7617
Beta = 0.109
Revenue TTM = 424.4m USD
EBIT TTM = -55.2m USD
EBITDA TTM = -48.3m USD
Long Term Debt = 75.0m USD (from longTermDebt, last quarter)
Short Term Debt = 6.95m USD (from shortTermDebt, last quarter)
Debt = 103.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 72.9m USD (from netDebt column, last quarter)
Enterprise Value = 517.0m USD (444.1m + Debt 103.2m - CCE 30.3m)
Interest Coverage Ratio = -5.09 (Ebit TTM -55.2m / Interest Expense TTM 10.8m)
FCF Yield = -2.53% (FCF TTM -13.1m / Enterprise Value 517.0m)
FCF Margin = -3.08% (FCF TTM -13.1m / Revenue TTM 424.4m)
Net Margin = -15.53% (Net Income TTM -65.9m / Revenue TTM 424.4m)
Gross Margin = 14.60% ((Revenue TTM 424.4m - Cost of Revenue TTM 362.4m) / Revenue TTM)
Gross Margin QoQ = 13.10% (prev 16.52%)
Tobins Q-Ratio = 3.24 (Enterprise Value 517.0m / Total Assets 159.8m)
Interest Expense / Debt = 1.81% (Interest Expense 1.87m / Debt 103.2m)
Taxrate = 0.76% (-131.0k / -17.1m)
NOPAT = -54.8m (EBIT -55.2m * (1 - 0.76%)) [loss with tax shield]
Current Ratio = 1.62 (Total Current Assets 104.8m / Total Current Liabilities 64.8m)
Debt / Equity = -11.48 (negative equity) (Debt 103.2m / totalStockholderEquity, last quarter -8.98m)
Debt / EBITDA = -1.51 (negative EBITDA) (Net Debt 72.9m / EBITDA -48.3m)
Debt / FCF = -5.57 (negative FCF - burning cash) (Net Debt 72.9m / FCF TTM -13.1m)
Total Stockholder Equity = 3.79m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.23% (Net Income -65.9m / Total Assets 159.8m)
RoE = -1739 % (out of range, set to none) (Net Income TTM -65.9m / Total Stockholder Equity 3.79m)
RoCE = -70.02% (EBIT -55.2m / Capital Employed (Equity 3.79m + L.T.Debt 75.0m))
RoIC = -62.81% (negative operating profit) (NOPAT -54.8m / Invested Capital 87.2m)
WACC = 5.55% (E(444.1m)/V(547.3m) * Re(6.42%) + D(103.2m)/V(547.3m) * Rd(1.81%) * (1-Tc(0.01)))
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 256.2%
Fair Price DCF = unknown (Cash Flow -13.1m)
EPS Correlation: 75.75 | EPS CAGR: 58.12% | SUE: 3.24 | # QB: 1
Revenue Correlation: 98.25 | Revenue CAGR: 24.92% | SUE: -0.02 | # QB: 0

Additional Sources for TOI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle